PlantForm and PharmaPraxis Establish Joint Biosimilar Development Venture - - BioPharm International

ADVERTISEMENT

PlantForm and PharmaPraxis Establish Joint Biosimilar Development Venture


PlantForm and PharmaPraxis announce plans to developm six biopharmaceutical targets for the Brazilian market.

PlantForm Corporation of Canada and PharmaPraxis of Brazil have announced a joint venture to develop, manufacture and commercialize biosimilar and/or biobetter versions of six biopharmaceuticals for the Brazilian market, using PlantForm’s manufacturing system.

The joint venture will first develop a biosimilar/biobetter version of the oncology drug Avastin (bevacizumab), in collaboration with the Fraunhofer Center for Molecular Biology in Newark, Del., which will produce the active pharmaceutical ingredient (API) for clinical trials.

Brazilian government corporation Bio-Manguinhos will also participate in the project. Bio-Manguinhos is responsible for technology development and production of vaccines, reagents and biopharmaceuticals to meet public health demands.

The joint venture will build a pilot cGMP biopharmaceutical manufacturing facility in Brazil.

Source: PlantForm

 

 

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

AbbVie/Shire Deal Officially Off
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Lilly to Close Manufacturing Facility in Puerto Rico
October 17, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Author Guidelines

Click here